An overview of immune checkpoint inhibitors in breast cancerFederica Miglietta, Nicla La Verde, Maria Silvia Cona et al.|Exploration of Targeted Anti-tumor Therapy|2020Cited by 7
Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2.Claudio Vernieri, Marta Piras, Marianna Sirico et al.|Journal of Clinical Oncology|2024Cited by 7
Abstract P2-09-26: Real world progression free survival in elderly vs. younger HR+/HER2- advanced breast cancer patients treated with first-line endocrine therapy plus CDK4/6i: a sub-analysis of the multicenter, PALMARES-2 studyFrancesca Ligorio, Claudio Vernieri, Leonardo Provenzano et al.|Clinical Cancer Research|2025Cited by 0